177 related articles for article (PubMed ID: 7539119)
1. Introduction of a loss-of-function point mutation from the SH3 region of the Caenorhabditis elegans sem-5 gene activates the transforming ability of c-abl in vivo and abolishes binding of proline-rich ligands in vitro.
Van Etten RA; Debnath J; Zhou H; Casasnovas JM
Oncogene; 1995 May; 10(10):1977-88. PubMed ID: 7539119
[TBL] [Abstract][Full Text] [Related]
2. Mutational analysis of the regulatory function of the c-Abl Src homology 3 domain.
Brasher BB; Roumiantsev S; Van Etten RA
Oncogene; 2001 Nov; 20(53):7744-52. PubMed ID: 11753652
[TBL] [Abstract][Full Text] [Related]
3. Mutation of a phenylalanine conserved in SH3-containing tyrosine kinases activates the transforming ability of c-Abl.
Jackson PK; Paskind M; Baltimore D
Oncogene; 1993 Jul; 8(7):1943-56. PubMed ID: 8510937
[TBL] [Abstract][Full Text] [Related]
4. Characterization of the proline-rich region of mouse MAPKAP kinase 2: influence on catalytic properties and binding to the c-abl SH3 domain in vitro.
Plath K; Engel K; Schwedersky G; Gaestel M
Biochem Biophys Res Commun; 1994 Sep; 203(2):1188-94. PubMed ID: 8093038
[TBL] [Abstract][Full Text] [Related]
5. An intramolecular SH3-domain interaction regulates c-Abl activity.
Barilá D; Superti-Furga G
Nat Genet; 1998 Mar; 18(3):280-2. PubMed ID: 9500553
[TBL] [Abstract][Full Text] [Related]
6. Analysis of chimeric Gag-Arg/Abl molecules indicates a distinct negative regulatory role for the Arg C-terminal domain.
Mysliwiec T; Perego R; Kruh GD
Oncogene; 1996 Feb; 12(3):631-40. PubMed ID: 8637720
[TBL] [Abstract][Full Text] [Related]
7. Drosophila abelson interacting protein (dAbi) is a positive regulator of abelson tyrosine kinase activity.
Juang JL; Hoffmann FM
Oncogene; 1999 Sep; 18(37):5138-47. PubMed ID: 10498863
[TBL] [Abstract][Full Text] [Related]
8. Transactivation of Abl by the Crk II adapter protein requires a PNAY sequence in the Crk C-terminal SH3 domain.
Reichman C; Singh K; Liu Y; Singh S; Li H; Fajardo JE; Fiser A; Birge RB
Oncogene; 2005 Dec; 24(55):8187-99. PubMed ID: 16158059
[TBL] [Abstract][Full Text] [Related]
9. Phosphorylation of c-Abl by protein kinase Pak2 regulates differential binding of ABI2 and CRK.
Jung JH; Pendergast AM; Zipfel PA; Traugh JA
Biochemistry; 2008 Jan; 47(3):1094-104. PubMed ID: 18161990
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase.
Oda T; Kujovich J; Reis M; Newman B; Druker BJ
Oncogene; 1997 Sep; 15(11):1255-62. PubMed ID: 9315092
[TBL] [Abstract][Full Text] [Related]
11. Coupling of the murine protein tyrosine phosphatase PEST to the epidermal growth factor (EGF) receptor through a Src homology 3 (SH3) domain-mediated association with Grb2.
Charest A; Wagner J; Kwan M; Tremblay ML
Oncogene; 1997 Apr; 14(14):1643-51. PubMed ID: 9135065
[TBL] [Abstract][Full Text] [Related]
12. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
Ren SY; Xue F; Feng J; Skorski T
Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
[TBL] [Abstract][Full Text] [Related]
13. Single point mutations in the SH2 domain impair the transforming potential of vav and fail to activate proto-vav.
Katzav S
Oncogene; 1993 Jul; 8(7):1757-63. PubMed ID: 8510922
[TBL] [Abstract][Full Text] [Related]
14. Mutagenic analysis of Vav reveals that an intact SH3 domain is required for transformation.
Groysman M; Nagano M; Shaanan B; Katzav S
Oncogene; 1998 Sep; 17(12):1597-606. PubMed ID: 9794237
[TBL] [Abstract][Full Text] [Related]
15. Mutagenic analysis of functional domains of the mos proto-oncogene and identification of the sites important for MAPK activation and DNA binding.
Fukasawa K; Zhou R; Matten WT; Armstrong AJ; Daar I; Oskarsson M; Sathyanarayana BK; Maclvor L; Wood TG; Vande Woude GF
Oncogene; 1995 Oct; 11(8):1447-57. PubMed ID: 7478569
[TBL] [Abstract][Full Text] [Related]
16. Binding of the proline-rich segment of myelin basic protein to SH3 domains: spectroscopic, microarray, and modeling studies of ligand conformation and effects of posttranslational modifications.
Polverini E; Rangaraj G; Libich DS; Boggs JM; Harauz G
Biochemistry; 2008 Jan; 47(1):267-82. PubMed ID: 18067320
[TBL] [Abstract][Full Text] [Related]
17. Imatinib mesylate (STI571)-induced cell edge translocation of kinase-active and kinase-defective Abelson kinase: requirements of myristoylation and src homology 3 domain.
Fujita A; Shishido T; Yuan Y; Inamoto E; Narumiya S; Watanabe N
Mol Pharmacol; 2009 Jan; 75(1):75-84. PubMed ID: 18835981
[TBL] [Abstract][Full Text] [Related]
18. Crystal structure of the abl-SH3 domain complexed with a designed high-affinity peptide ligand: implications for SH3-ligand interactions.
Pisabarro MT; Serrano L; Wilmanns M
J Mol Biol; 1998 Aug; 281(3):513-21. PubMed ID: 9698566
[TBL] [Abstract][Full Text] [Related]
19. Evidence for SH3 domain directed binding and phosphorylation of Sam68 by Src.
Shen Z; Batzer A; Koehler JA; Polakis P; Schlessinger J; Lydon NB; Moran MF
Oncogene; 1999 Aug; 18(33):4647-53. PubMed ID: 10467411
[TBL] [Abstract][Full Text] [Related]
20. Sequence specificity in the recognition of the epidermal growth factor receptor by the abl Src homology 2 domain.
Zhu G; Decker SJ; Maclean D; McNamara DJ; Singh J; Sawyer TK; Saltiel AR
Oncogene; 1994 May; 9(5):1379-85. PubMed ID: 8152798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
